Classical psychedelics like psilocybin, LSD, and mescaline are illegal Schedule I drugs (meaning the DEA says they have no medical use). Rescheduling means moving them to a lower schedule so doctors can prescribe them. The FDA and DEA both have to approve this, and the whole process—from an FDA recommendation to final DEA approval—takes 18–24 months. No psychedelic company has filed the paperwork for FDA approval yet, so the earliest an FDA recommendation could come is 2026–2027, making 2028 the earliest possible rescheduling date.
No FDA approval recommendation for any classical psychedelic (psilocybin, LMA, mescaline) is currently on a timeline that would allow DEA scheduling completion before 2028. MDMA-assisted therapy was rejected in 2024; psilocybin NDA submissions are not yet filed. DEA scheduling reviews historically take 18-24 months after FDA recommendation. This prediction is well-grounded in procedural reality. Resolve date corrected to 2028-01-01 to match the substantive claim; the original 2026-08-06 resolve date was internally inconsistent with the 'before 2028' claim.